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SUMMARY
Osteonecrosis of the jaw (ONJ) is a rare adverse event of antiresorptive drugs such as bisphosphonates (BP) 
and denosumab (DMAb).
The diagnosis of ONJ is considered in cases where exposed bone in the maxillofacial region does not heal 
within 8 weeks in a patient previously treated with an antiresorptive agent. In patients with osteoporosis, 
ONJ is reported as a very rare adverse event while in oncologic patients with bone metastases or malignant 
hypercalcemia the incidence is significantly higher (up to the 1-10% of the patients). The pathophysiology of 
ONJ is still not completely understood but it is multi-factorial. ONJ is a condition associated with poor oral 
health, oral surgery, and use of antiresorptive agents. Prevention is of paramount importance especially in cancer 
patients, in whom the large majority of cases of ONJ (>90%) are reported, but it should also be considered 
in osteoporotic patients, especially during dental surgical procedure. Some simple prevention procedures are 
effective in reducing the risk of its appearance. When ONJ unfortunately occurs, the large majority of patients 
can be managed conservatively.
In conclusion, ONJ is a rare condition associated with antiresorptive drugs. Both osteoporotic and oncologic 
patients should be well informed about its low absolute risk and regarding the fact that the benefits of 
antiresorptive therapy far outweigh this potential risk of ONJ. 
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n	 INTRODUCTION
Osteonecrosis of the jaw (ONJ) is a rare condition and a possible adverse event 
of bisphosphonates (BP) or denosumab 
(DMAb). It was reported for the first time 
in 2003 (1), when 36 cancer patients receiv-
ing treatment with pamidronate or zoledro-
nate developed a painful bone exposure of 
the mandible, of the maxilla or both, unre-
sponsive to surgical and medical treatment. 
Since then, several case reports have been 
published as well as retrospective and lim-
ited prospective data, showing that more 
than 90% of the cases of ONJ occurred 
in oncologic patients who were receiving 
high doses of antiresorptive therapy (2).
n	 CLINICAL DIAGNOSIS
The International Task Force on ONJ (3) 
defines ONJ as:
1. Presence of exposed bone in the max-
illofacial region which does not heal 
within 8 weeks after identification by a 
health care provider;
2. Exposure to an antiresorptive agent (BP 
or DMAb);
3. No history of radiation therapy to the 
craniofacial region.
The diagnosis of ONJ can be made ac-
cording to these clinical criteria only af-
ter the exclusion of other possible causes 
of odontalgia. Several more common dis-
eases should be taken into account prior to 
suspecting an early phase of ONJ, such as 
periodontal or apical abscess, pulpitis, si-
nusitis, dental caries, mucosal ulceration or 
cancer, etc.
Patient history and clinical examination 
remain the most sensitive diagnostic tools. 
After a thorough evaluation, the persis-
tence of exposed bone in the oral cavity for 
8 weeks or longer without any response to 
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ture might lead to over-diagnosis of ONJ, 
since the same presentation of symptoms 
may be related to several alternative diag-
noses (3) (Figure 1). Indeed, only about 
50% of individuals with such lesions de-
velop a real ONJ. 
n	 EPIDEMIOLOGY
When considering drug safety for the man-
agement of osteoporosis, ONJ is reported 
as a very rare adverse event (less than 1 
case for every 1000 patients treated) as-
sociated with the use of BP and DMAb 
(4). In view of such a low incidence, it is 
not surprising that ONJ was not reported 
appropriate therapy is the hallmark of ONJ.
Findings on plain film imaging or on com-
puted tomography (CT) are non-specific. 
The presence of areas of focal sclerosis, 
thickened lamina dura and reactive peri-
osteal bone may only help the clinician 
to predict possible future sites of exposed 
necrotic bone (3). Plain films, CT, MRI, 
bone scanning, and positron emission to-
mography may also be useful in assisting 
the staging and the scheduling of surgical 
interventions (3).
n	 STAGING
ONJ may remain asymptomatic for long 
periods, ranging from weeks to several 
months or years (3). For this reason, the 
International Task Force on ONJ recom-
mended a specific staging, as reported in 
Table I and Figure 1 (3).
Some scientific societies (such as 
AAOMS: American Association of Oral 
and Maxillofacial Surgeons) proposed an 
early prodromal phase defined as stage 0, 
including individuals treated with antire-
sorptive therapy complaining of pain and 
with radiographic features of osteosclero-
sis (3). However, the Task Force agreed 
not to consider this stage 0 terminology, 
in order to avoid the risk that this fea-
Figure 1 - Staging of ONJ according to different scientific societies.
Table I - ONJ staging recommended by Task Force.
Stage 1: disease is described as the presence of 
exposed bone in asymptomatic patients with no evi-
dence of significant adjacent or regional soft tissue 
inflammation or infection. 
Stage 2: disease is characterized by exposed bone 
in the oral cavity in association with pain, soft tissue 
swelling, or secondary infection. 
Stage 3: disease is characterized by exposed bone in 
association with pain, soft tissue swelling, or infection 
as well as pathologic fracture or extra-oral fistula or 
oral antral fistula or radiographic evidence of osteoly-
sis extending to the inferior border of the mandible or 
the floor of the maxillary sinus.
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for many years during pivotal osteoporosis 
BP studies. In addition, it could explain the 
difficulties in the accurate evaluation of the 
real incidence of the disease.
In the Health Outcomes and Reduced In-
cidence with Zoledronic Acid Once Yearly 
(HORIZON) pivotal fracture trial, involv-
ing 3889 patients, two cases of potential 
ONJ were identified (one in the placebo 
group and one in the zoledronic-acid 
group) (5).
In oncologic patients with bone metastases 
or malignant hypercalcemia, the context is 
very different, since they are exposed to a 
much more intensive osteoclast inhibition. 
These patients are usually treated with dos-
ages ten times greater than those used for 
osteoporosis. 
In this population the incidence of ONJ is 
more accurately estimated and appears to 
be significantly higher (up to 1-10% of the 
patients) (3, 6).
Recently some clinical trials, with an 
identical design, compared denosumab to 
zoledronic acid in the prevention of skel-
etal-related events (pathologic fracture, 
radiation therapy for the bone, bone and 
spinal cord compression) in over 5700 pa-
tients with breast cancer, prostate cancer, 
multiple myeloma or solid tumors with 
bone metastasis. The pooled data were also 
used to study the incidence, the risk fac-
tors and the outcomes of ONJ (7). In total, 
89 cases of ONJ cases were documented 
and the incidence in the DMAb arm was 
1.8% vs 1.3% in the zoledronic acid arm (a 
non-statistically significant difference) (7). 
With a such low incidence of ONJ, the ben-
efit of the high-dose antiresorptive therapy 
largely outweighs the risk of ONJ by a fac-
tor of 17 (3). 
The incidence of ONJ in cancer patients 
appears to be related to many factors such 
as the dose used, the duration of the treat-
ment, the specific kind of malignancy 
(with a higher risk in patients with breast 
or prostate cancer or with multiple my-
eloma) (8). 
Furthermore, the use of concurrent drugs 
potentially interfering with bone health 
should be considered (i.e. glucocorticoids 
or antiangiogenic drugs) (3).
n	 RISK FACTORS
The lack of consistent epidemiological 
data concerning ONJ has made it very dif-
ficult to define the risk factors. The Task 
Force proposed the following risk factors 
as significant for the development of ONJ 
in the oncology population, in decreasing 
order of importance (3):
1. use of i.v. BP (both cumulative dose 
and duration of exposure impact ONJ 
risk);
2. use of DMAb (both cumulative dose and 
duration of exposure impact ONJ risk);
3. radiation therapy;
4. dental extraction;
5. chemotherapy;
6. periodontal disease;
7. use of oral BP;
8. osteoporosis;
9. local suppuration;
10. glucocorticoid therapy;
11. diabetes;
12. denture use;
13. erythropoietin therapy;
14. tobacco use;
15. hyperthyroidism;
16. renal dialysis;
17. cyclophosphamide therapy;
18. increasing age.
When the osteoporosis patient population 
was considered, the Task Force considered 
as significant a smaller number of risk fac-
tors for the development of ONJ, in de-
creasing order of importance (3):
1. suppuration;
2. use of BP (duration of treatment impact 
ONJ risk);
3. dental extraction;
4. anemia.
A previous paper (9) studied the most com-
mon items associated with non-cancer-
related cases of ONJ and found that, simi-
larly to the oncologic population, invasive 
dental procedures (i.e. tooth extraction, 
oral surgery) were the most common risk 
factor. In Italy dental implant is the most 
common cause for the discontinuation of 
osteoporosis treatment with BP or DMAb, 
even if there is currently no evidence for 
dental implant as a risk factor for ONJ even 
in cancer patients. Recent reviews also stat-
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ed that successful implant therapy is pos-
sible in patients receiving antiresorptive 
therapy (10-12).
Among the concomitant medical issues 
besides periodontal disease or other oral 
conditions, rheumatoid arthritis and dia-
betes were also reported, while the most 
commonly used medication affecting bone 
metabolism was glucocorticoid therapy 
(9). Several effects of glucocorticoids may 
contribute to increased risk of ONJ, such 
as inhibition of the osteoblast function, in-
creased osteoblast and osteocyte apoptosis, 
increased bone resorption, immunosup-
pression, impaired wound healing and in-
creased risk of local infection (2).
n	 PATHOPHYSIOLOGY
The relatively recent observation that not 
only BP but also DMAb may cause the 
appearance of ONJ made it necessary to 
research for the mechanisms common to 
both interventions. BP promote osteoclast 
apoptosis and deposit in the bone, where 
they persist for a long time. On the con-
trary, DMAb does not accumulate inside 
the bone and inhibits osteoclastic bone re-
sorption without causing apoptosis (13). 
The pathophysiology of ONJ is not yet ful-
ly understood but it is certainly multi-fac-
torial (14). Here we report the main known 
mechanisms underlying this condition. 
n	 INFECTION
ONJ is a pathological condition occurring 
only in the jaw bones, which have cer-
tain precise anatomical and microbiologi-
cal features that cannot be found in other 
bones of the body and that predispose them 
to bacterial infection (15):
1. the teeth erupt from the jawbone, break-
ing through the oral epithelium and al-
lowing infectious agents residing in the 
oral cavity to invade the jawbone via 
the gap between the epithelium and the 
teeth or via the root canal;
2. the oral mucosa covering the jawbone is 
thin, and thus infection caused by mu-
cosal injury can spread to the jawbone 
beneath the mucosa;
3. more than 800 types of resident bacteria 
inhabit dental plaque and can represent 
a source of infection in the oral cavity;
4. inflammation due to tooth decay, pul-
pitis, periapical lesions, or periodontal 
disease extends to the jawbone;
5. the jawbone is exposed to the oral cav-
ity following invasive dental treatments 
including tooth extraction, leading to 
infection.
The major histopathological finding in 
ONJ is chronic osteomyelitis accompa-
nied by osteonecrosis (15). Actinomyces 
colonies (resident bacteria in the oral cav-
ity) are frequently found in contact with 
necrotic bones in ONJ lesions, supporting 
the possibility that Actinomyces bacteria 
could play a key role in the pathogenesis 
of ONJ (16). Bacteria also stimulate bone 
resorption through the production of local 
cytokines and contribute to bone necrosis. 
In this context, there is evidence that the 
occurrence of ONJ is significantly reduced 
by the treatment of the oral infection via 
extensive oral health control, thus suggest-
ing that infection is a key step towards the 
development of ONJ (3, 15).
n	 SUPPRESSION OF BONE 
TURNOVER
Even though BP and DMAb, both potent 
antiresorptive drugs, have different mo-
lecular mechanisms of action, both are as-
sociated with ONJ. Thus, it is quite natural 
to consider the suppression of bone re-
sorption and of bone turnover as possible 
mechanisms in the development of ONJ.
Furthermore, the risk of ONJ increases 
with both the cumulative dose and the du-
ration of exposure to the treatment (2, 3, 
15). This pathogenetic hypothesis would 
explain the appearance of ONJ through 
an excessive inhibition of bone remodel-
ing and therefore resulting in an impaired 
osteoclast activity, too inadequate to allow 
the healing of the extraction socket (2). The 
studies cited above are consistent with this 
hypothesis, although ONJ has never been 
reported in other conditions associated 
with low bone turnover.
Very recently, two cases of ONJ have also 
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been reported in patients treated with ro-
mosozumab (17). Romosozumab is a 
monoclonal antibody that binds sclerostin 
and acts as a potent bone anabolic agent. 
This drug increases bone formation but 
also decreases bone resorption at the same 
time (17). This latter effect might possibly 
explain the development of ONJ.
n	 BONE/MUCOSAL INJURY
We have already discussed the predisposi-
tion of jaw bones to bacterial infections. 
Obviously, any cause of injury to the oral 
mucosa and/or the bone can contribute to 
infection, therefore infections themselves 
can contribute to further mucosal dam-
age. This fact explains why invasive den-
tal procedures (e.g. tooth extraction, oral 
surgery) are the most common risk factors 
for ONJ (3, 9). In the same way, other risk 
factors may also be responsible for reduc-
ing the mucosal defenses: glucocorticoids, 
tobacco use, diabetes, rheumatoid arthritis, 
radiation and chemotherapy, etc.
n	 VASCULARITY
The possible role of a deficit in vascular-
ity has been hypothesized, since ONJ has 
been also described in some cancer patients 
treated with antiangiogenic agents such as 
sunitinib and bevacizumab (3, 15), though 
all these patients had other risk factors for 
ONJ. BP are known to have antiangiogenic 
properties although animal studies with 
these drugs do not support any diminu-
tion of the vascular volume associated with 
their administration (3). DMAb is currently 
not known to have any antiangiogenic ef-
fect.
n	 GENETICS
We still do not know why, given that mil-
lions of patients take antiresorptive drugs 
and have similar risk factors, only such 
a small number of them develop ONJ. It 
has been suggested that polymorphisms in 
the farnesyl pyrophosphate synthase (18) 
or cytochrome P450 CYP2C8 genes (19) 
could predispose some individuals to ONJ. 
n	 PREVENTION
As previously discussed, ONJ is a condi-
tion associated with poor oral health, oral 
surgery, and use of potent antiresorptive 
agents. In the attempt to prevent ONJ, opti-
mizing oral health prior to the initiation of 
BP and DMAB therapy is emphasized and 
it has been proven to be effective in reduc-
ing its risk (3). 
Recommendations include (3):
1. completion of necessary oral surgery 
prior to the initiation of antiresorptive 
therapy;
2. administration of antibiotics 2-4 days 
before and 7-10 days after the proce-
dure;
3. antimicrobial mouth rinsing;
4. appropriate closure of the wound fol-
lowing tooth extraction;
5. maintenance of good oral hygiene.
The large majority of cases (>90%) of ONJ 
have occurred in cancer patients. Therefore 
it is recommended by the Task Force (3)
that when these patients undergo invasive 
oral surgery, their antiresorptive therapy 
should be withheld until soft tissue heal-
ing has occurred, even though there is no 
evidence supporting this recommendation 
in terms of changing the outcome of the 
dental procedure. Since the pharmacologi-
cal effects of DMAb are transient and re-
versible, this recommendation could in any 
case be useful. On the contrary, since BP 
are characterized by long-term skeletal re-
tention, discontinuation of the treatment is 
not expected to have a significant and im-
mediate impact on bone remodeling. How-
ever, since the uptake of BP is considerably 
increased at sites of local bone injury, with-
holding the therapy after oral surgery may 
reduce the local deposition of the drug in 
the jaw bones.
In patients taking lower doses of antire-
sorptive therapy for osteoporosis, the risk 
of ONJ is extremely low and thus the dis-
continuation of oral BP is not essential 
prior to dental procedures, especially in 
patients with higher fracture risk (3, 20). 
In conclusion, in order to identify the best 
approach for each patient with concurrent 
antiresorptive treatment, it is necessary 
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to stratify the risk of ONJ and to weigh 
it against the risk of osteoporotic fracture 
and/or the risk of skeletal-related events in 
cancer patients.
n	 MANAGEMENT
The large majority of patients with ONJ 
can be managed conservatively (optimal 
oral hygiene, regular professional dental 
care, elimination of active dental and peri-
odontal disease, topical antibiotic mouth 
rinses and systemic antibiotic therapy). 
Teriparatide may be considered a con-
servative treatment choice for those with 
osteoporosis and without cancer or prior 
radiation therapy to bone (2, 3, 21). Sub-
jects with stage 3 ONJ may be considered 
for surgery with osteotomy of the affected 
area (2, 3).
n	 CONCLUSIONS
ONJ is an uncommon condition associ-
ated with antiresorptive treatment and with 
multiple further factors contributing to its 
pathophysiology. The large majority of 
cases (>90%) occur in cancer patients and 
simple prevention procedures are effective 
in reducing its risk.
Both osteoporotic and oncologic patients 
should be well informed about ONJ but also 
well reassured as to its low absolute risk and 
also correctly advised regarding the fact that 
the benefits of antiresorptive therapy far out-
weigh the potential risk of ONJ. 
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